Login to Your Account

CSL invests in key cardiovascular trial, option to buy transplant drug developer

By Michael Fitzhugh
Staff Writer

Tuesday, December 5, 2017

Australia's CSL Ltd. said it expects to spend between $450 million and $550 million on its largest-ever study, a phase III trial of CSL-112, an I.V. infusion formulation of human apolipoprotein A-I intended to reduce early recurrent cardiovascular events in heart attack survivors.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription